ARTELO BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
ARTELO BIOSCIENCES, INC. (ARTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $25.69 per share for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2022-11-08
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.29.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-11-30 was $0.00.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-11-30 was $0.00.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2019-11-30 was $0.00.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $3.31.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2019 was $0.00.
- ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2018 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2022-09-30 | $25.69 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.65 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $1.29 10-Q · filed 2022-05-12 | |||
| 2021-11-30 | $0.00 10-Q · filed 2022-01-12 | |||
| 2021-05-31 | $0.00 10-Q · filed 2021-07-12 | |||
| 2021-02-28 | $0.00 10-Q · filed 2021-04-13 | |||
| 2020-11-30 | $0.00 10-Q · filed 2021-01-14 | |||
| 2020-08-31 | $3.31 10-K · filed 2020-11-04 | |||
| 2020-05-31 | $3.31 10-Q · filed 2020-07-13 | |||
| 2020-02-29 | $3.31 10-Q · filed 2020-04-13 | |||
| 2019-11-30 | $0.00 10-Q · filed 2020-01-14 | |||
| 2019-08-31 | $0.00 10-K · filed 2020-11-04 | |||
| 2019-05-31 | $0.00 10-Q · filed 2019-07-15 | |||
| 2019-02-28 | $0.00 10-Q · filed 2019-04-15 | |||
| 2018-08-31 | $0.00 10-K/A · filed 2019-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |